Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Chief Financial Officer | January 20, 2026 | January 22, 2026 |
| TCR2 THERAPEUTICS INC.TCRR · Entity 94327 | Chief Financial Officer | December 14, 2020 | December 16, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NewAmsterdam Pharma Co N.V.
Report date January 20, 2026 · Filed January 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 58,382 |
Ending reported balance
After 2026-01-21 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-01-20 · Exercise / conversion · Acquired 60,216 · Balance 118,598 Row 2 · 2026-01-20 · Sale · Disposed 900 · Balance 117,698 F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: These shares were sold in multiple transactions at prices ranging from $30.17 per share to $30.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Row 3 · 2026-01-20 · Sale · Disposed 39,712 · Balance 77,986 F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3: These shares were sold in multiple transactions at prices ranging from $31.29 per share to $32.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Row 4 · 2026-01-20 · Sale · Disposed 19,604 · Balance 58,382 F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: These shares were sold in multiple transactions at prices ranging from $32.29 per share to $32.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Row 5 · 2026-01-21 · Exercise / conversion · Acquired 39,784 · Balance 98,166 Row 6 · 2026-01-21 · Sale · Disposed 15,422 · Balance 82,744 F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5: These shares were sold in multiple transactions at prices ranging from $32.48 per share to $33.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Row 7 · 2026-01-21 · Sale · Disposed 24,362 · Balance 58,382 F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6: These shares were sold in multiple transactions at prices ranging from $33.48 per share to $34.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.26 · Expires 2033-11-01 | Direct | 702,598 |
Reported balance
After 2026-01-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-20 · Exercise / conversion · Disposed 60,216 · Balance 702,598 F7: The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.26 · Expires 2033-11-01 | Direct | 662,814 |
Reported balance
After 2026-01-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-01-21 · Exercise / conversion · Disposed 39,784 · Balance 662,814 F7: The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: These shares were sold in multiple transactions at prices ranging from $30.17 per share to $30.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F3: These shares were sold in multiple transactions at prices ranging from $31.29 per share to $32.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F4: These shares were sold in multiple transactions at prices ranging from $32.29 per share to $32.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F5: These shares were sold in multiple transactions at prices ranging from $32.48 per share to $33.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F6: These shares were sold in multiple transactions at prices ranging from $33.48 per share to $34.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F7: The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
TCR2 THERAPEUTICS INC.
Report date December 14, 2020 · Filed December 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,473 |
Ending reported balance
After 2020-12-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-14 · Exercise / conversion · Acquired 2,000 · Balance 3,473 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 2 · 2020-12-14 · Sale · Disposed 2,000 · Balance 1,473 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2028-04-29 | Direct | 102,558 |
Reported balance
After 2020-12-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-14 · Exercise / conversion · Acquired 2,000 · Balance 102,558 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: 25% of this option shall vest and become exercisable on April 9, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: 25% of this option shall vest and become exercisable on April 9, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2026 Filed Jan 22, 2026 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (Right to Buy) · Derivative | 39,784 | $0.00 Strike: $9.26 | $0.00 |
DisclosureSEC source: 0001193125-26-019686 · ownership.xml · derivative · entry 9 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 662,814 Underlying: Ordinary Shares · 39,784 shares Expires 2033-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 24,362 | $33.80 | $823,435.60 |
DisclosureSEC source: 0001193125-26-019686 · ownership.xml · nonDerivative · entry 7 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,382 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: These shares were sold in multiple transactions at prices ranging from $33.48 per share to $34.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 15,422 | $33.25 | $512,781.50 |
DisclosureSEC source: 0001193125-26-019686 · ownership.xml · nonDerivative · entry 6 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,744 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: These shares were sold in multiple transactions at prices ranging from $32.48 per share to $33.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 39,784 | $9.26 | $368,399.84 |
DisclosureSEC source: 0001193125-26-019686 · ownership.xml · nonDerivative · entry 5 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (Right to Buy) · Derivative | 60,216 | $0.00 Strike: $9.26 | $0.00 |
DisclosureSEC source: 0001193125-26-019686 · ownership.xml · derivative · entry 8 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 702,598 Underlying: Ordinary Shares · 60,216 shares Expires 2033-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 19,604 | $32.38 | $634,777.52 |
DisclosureSEC source: 0001193125-26-019686 · ownership.xml · nonDerivative · entry 4 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,382 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: These shares were sold in multiple transactions at prices ranging from $32.29 per share to $32.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 39,712 | $31.78 | $1,262,047.36 |
DisclosureSEC source: 0001193125-26-019686 · ownership.xml · nonDerivative · entry 3 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,986 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: These shares were sold in multiple transactions at prices ranging from $31.29 per share to $32.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 900 | $30.64 | $27,576.00 |
DisclosureSEC source: 0001193125-26-019686 · ownership.xml · nonDerivative · entry 2 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,698 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: These shares were sold in multiple transactions at prices ranging from $30.17 per share to $30.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 22:24 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 60,216 | $9.26 | $557,600.16 |
DisclosureSEC source: 0001193125-26-019686 · ownership.xml · nonDerivative · entry 1 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 7, 2026 23:27 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 115,000 | $0.00 Strike: $35.45 | $0.00 |
DisclosureSEC source: 0001193125-26-006658 · ownership.xml · derivative · entry 3 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,000 Underlying: Ordinary Shares · 115,000 shares Expires 2036-01-07 F5 · derivative.exercise_date: 25% of the shares underlying the option will vest on Janaury 2, 2027, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 07, 2026 Filed Jan 7, 2026 23:27 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOrdinary Shares | 25,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-006658 · ownership.xml · nonDerivative · entry 2 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,382 F3 · shares: Represents RSUs, each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F4 · price: Each RSU was granted on January 7, 2026 for no consideration. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 23:27 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 5,118 | $33.25 | $170,173.50 |
DisclosureSEC source: 0001193125-26-006658 · ownership.xml · nonDerivative · entry 1 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,882 F1 · kind: Represents pre-arranged sale of shares by the Reporting Person solely to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs) pursuant to sell-to-cover agreement entered into with the Issuer. The sale does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.77 to $33.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:25 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (Right to Buy) · Derivative | 14,900 | $0.00 Strike: $9.26 | $0.00 |
DisclosureSEC source: 0000950170-25-010594 · ownership.xml · derivative · entry 8 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 762,814 Underlying: Ordinary Shares · 14,900 shares Expires 2033-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:25 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 3,405 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-010594 · ownership.xml · nonDerivative · entry 6 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: These shares were sold in multiple transactions at prices ranging from $21.93 per share to $22.41 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:25 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 11,495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-010594 · ownership.xml · nonDerivative · entry 5 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,405 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: These shares were sold in multiple transactions at prices ranging from $20.93 per share to $21.92 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:25 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 14,900 | $9.26 | $137,974.00 |
DisclosureSEC source: 0000950170-25-010594 · ownership.xml · nonDerivative · entry 4 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:25 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (Right to Buy) · Derivative | 46,983 | $0.00 Strike: $9.26 | $0.00 |
DisclosureSEC source: 0000950170-25-010594 · ownership.xml · derivative · entry 7 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 777,714 Underlying: Ordinary Shares · 46,983 shares Expires 2033-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:25 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 13,304 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-010594 · ownership.xml · nonDerivative · entry 3 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,000 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: These shares were sold in multiple transactions at prices ranging from $23.38 per share to $23.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:25 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 33,679 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-010594 · ownership.xml · nonDerivative · entry 2 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,304 F1 · kind: This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: These shares were sold in multiple transactions at prices ranging from $22.38 per share to $23.37 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:25 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 46,983 | $9.26 | $435,062.58 |
DisclosureSEC source: 0000950170-25-010594 · ownership.xml · nonDerivative · entry 1 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:08 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOrdinary Shares | 38,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-002973 · ownership.xml · nonDerivative · entry 1 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 F1 · shares: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F2 · price: Each RSU was granted on January 7, 2025 for no consideration. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:53 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 220,000 | $0.00 Strike: $25.96 | $0.00 |
DisclosureSEC source: 0000950170-25-002369 · ownership.xml · derivative · entry 1 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,000 Underlying: Ordinary Shares · 220,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest on January 2, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:10 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 80,000 | $0.00 Strike: $11.17 | $0.00 |
DisclosureSEC source: 0000950170-24-001104 · ownership.xml · derivative · entry 1 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Ordinary Shares · 80,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest on January 1, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 16:02 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0000899243-20-034089 · doc4.xml · derivative · entry 3 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,558 Underlying: Common Stock · 2,000 shares Expires 2028-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on April 9, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 16:02 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 2,000 | $35.00 | $70,000.00 |
DisclosureSEC source: 0000899243-20-034089 · doc4.xml · nonDerivative · entry 2 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,473 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 16:02 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionCommon Stock | 2,000 | $5.88 | $11,760.00 |
DisclosureSEC source: 0000899243-20-034089 · doc4.xml · nonDerivative · entry 1 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 06:20 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantStock Option (Right to Buy) · Derivative | 92,000 | $0.00 Strike: $31.83 | $0.00 |
DisclosureSEC source: 0000899243-20-033479 · doc4.xml · derivative · entry 2 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2030-12-09 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 17:00 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001209191-20-059443 · doc4.xml · derivative · entry 4 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,558 Underlying: Common Stock · 2,000 shares Expires 2028-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on April 9, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 17:00 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 1,666 | $30.00 | $49,980.00 |
DisclosureSEC source: 0001209191-20-059443 · doc4.xml · nonDerivative · entry 3 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,473 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 17:00 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 2,000 | $30.00 | $60,000.00 |
DisclosureSEC source: 0001209191-20-059443 · doc4.xml · nonDerivative · entry 2 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,139 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 17:00 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | Exercise / conversionCommon Stock | 2,000 | $5.88 | $11,760.00 |
DisclosureSEC source: 0001209191-20-059443 · doc4.xml · nonDerivative · entry 1 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 28, 2020 Filed Mar 27, 2020 16:11 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantCommon Stock | 1,473 | $10.10 | $14,877.30 |
DisclosureSEC source: 0001209191-20-021376 · doc4.xml · nonDerivative · entry 2 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,139 F3 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the ESPP for the ESPP purchase period of September 2, 2019 through February 28, 2020. This transaction is exempt under Rule 16b-3(c). F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2020. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 19:36 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $16.10 | $0.00 |
DisclosureSEC source: 0000899243-19-029852 · doc4.xml · derivative · entry 1 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-12-18 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2021, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| August 30, 2019 Filed Mar 27, 2020 16:11 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantCommon Stock | 1,666 | $12.75 | $21,241.50 |
DisclosureSEC source: 0001209191-20-021376 · doc4.xml · nonDerivative · entry 1 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,666 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of February 13, 2019 through August 30, 2019. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 13, 2019. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 16:06 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | GrantStock Option (Right to Buy) · Derivative | 152,307 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0001750019-19-000022 · wf-form4_155509959836134.xml · derivative · entry 1 Somaiya Mayur Ian · CIK 0001760303 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,307 Underlying: Common Stock · 152,307 shares Expires 2029-04-10 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.